Global Non-alcoholic Steatohepatitis Therapeutics Market

Non-alcoholic Steatohepatitis Therapeutics Market size was valued at US$ 10.58 Bn. in 2022 and the total Non-alcoholic Steatohepatitis Therapeutics revenue is expected to grow at 21.3% through 2023 to 2029, reaching nearly US$ 40.91 Bn.

Non-alcoholic Steatohepatitis Therapeutics Market Overview:

Non-alcoholic fatty liver disease (NAFLD) is a relatively prevalent ailment that refers to a range of disorders in which excess fat accumulates in the liver of individuals who consume little or no alcohol. The most common kind of NAFLD is fatty liver, which is a curable condition. Fat accumulates in the liver cells of people with fatty liver. Despite having fat in the liver is not natural, it is unlikely to harm the liver on its own.

To know about the Research Methodology :- Request Free Sample Report

A tiny percentage of NAFLD patients may have a more dangerous illness known as non-alcoholic steatohepatitis (NASH). Fat buildup in NASH is related to hepatic cells inflammation and varying degrees of scarring. NASH is a potentially fatal illness that can result in extensive scarring of the liver and cirrhosis. Cirrhosis develops when the liver experiences significant injury and the hepatic cells are eventually replaced by scar tissue, resulting in the liver's inability to function normally. Cirrhosis may ultimately necessitate a liver transplant (operation to remove the diseased liver and substitute it with a fresh liver) for certain people.

In this report, the Non-alcoholic Steatohepatitis Therapeutics market's growth reasons, as well as the market's many segments (Diagnostic, Drug, Distribution Channel and Region), are discussed. Data has been given by market players, regions, and specific requirements. This market report includes a comprehensive overview of all the significant improvements that are presently prevailing in all market segments. Key data analysis is presented in the form of statistics, infographics, and presentations. The study discusses the Non-alcoholic Steatohepatitis Therapeutics market's Drivers, Restraints, Opportunities, and Challenges. The report helps to assess the market growth drivers and determines how to use these drivers as a tool. The report also helps to rectify and resolve issues related to the global Non-alcoholic Steatohepatitis Therapeutics market situation.

Non-alcoholic Steatohepatitis Therapeutics Market Dynamics:

A primary driver of the market in the forecast period is expected to be the fact that many coronavirus patients have been diagnosed with liver diseases.

The etiology of coronavirus liver injury can be related to a variety of reasons, namely virus-induced inflammatory responses, hypoxia, hepatic obstruction, and drug-induced liver problems. Coronavirus has been linked to hepatic damage and liver-related fatality in cirrhotic individuals. The impact of coronavirus on health services has had a negative influence on the care delivery and the prognosis of patients with chronic liver disease. As a result, there has been a drop in the therapy, detection, and follow-up of individuals with liver problems, which has had a severe impact on the healthcare business as a whole. Furthermore, drug clinical trials have stalled since most corporations have postponed the launch of most new studies in various nations.

The cost-cutting pressures from regulatory bodies are a major challenge in the market growth.

Governments in both rich and developing nations are advocating cost-cutting initiatives such as lowering prescription coverage costs and increasing the usage of generic medications. Governments, insurers, and individuals are putting substantial cost-cutting pressure on drug makers all around the world. This lower pricing pressure is leading to increased medication acceptance in emerging economies, where there is a considerable need for low-cost treatments. This, however, has a negative impact on the performance of various pharmaceutical businesses. This trend is supposed to continue in the future years due to ongoing demand from insurers, and personal and corporate payers to reduce pharma pricing due to worries about providing more innovative drugs to treat prevalent ailments.

The key opportunity in the market is rising research and development investments in pharmaceutical companies.

Pharmaceutical and businesses' increasing R&D expenditures are leading them to seek seamless integration or multifunctional outsourcing solutions for drug research and development, from the early development phase through the late-stage design phase. Outsourcing has grown as a strategic solution to offset the shortage of in-house resources necessary for product innovation as pharma businesses face massive pressure to limit operating expenses. Large pharmaceutical corporations are shifting to a simpler business strategy that mainly depends on outsourcing. Most pharmaceutical and businesses outsource their testing facilities throughout research and development to increase profit margins, meet drug discovery timeframes, and save money.

Non-alcoholic Steatohepatitis Therapeutics Market Segment Analysis:

(Currently, there are no medicines available in the market that can completely reverse the liver damage from NASH; however, there are certain medicines available that can alleviate the early-stage NASH damage. We have covered these medicines in our report. )

By Drug, Ocaliva or OCA is a promising medicine in NASH treatment. It has certain side effects and efficacy issues that are under experimentation.

1.Intercept pharmaceutical's initial effort to obtain speedy clearance was denied by the FDA in 2022. It has returned with further biopsy and safety data to support the company's second approval request.

2.However, NASH specialists cautioned that the first uptake may be delayed owing to the possibility of biopsies being required by the FDA or payers.

3.The drug's adverse effects of itch and a rise in LDL-cholesterol may also be a problem for prescribers, necessitating further training and patient supervision.

Even though Intercept Pharmaceuticals' obeticholic acid (OCA) has a better chance of approval in its second test in nonalcoholic steatohepatitis (NASH), experts are still skeptical about its early adoption chances. The FDA's or insurers' requirements for liver biopsy may delay utilization, and its long-term safety will necessitate physician counseling and supervision.

In primary biliary cirrhosis, OCA is sold as Ocaliva and costs roughly $7900 for a supply of Thirty 5mg pills. Intercept stated that its OCA safety data is more than twice as large as what it revealed for its interim review. In 2019, the data was based on 1,900 individuals who had been exposed to the medicine for an average of 15 months. The new research comes from 2,500 people who were exposed for an average of 30 months. Furthermore, 650 of these individuals had been on OCA for at least 48 months.

Non-alcoholic Steatohepatitis Therapeutics Market Regional Insights:

As per a global 2019 research liver illness accounts for roughly 1.9 million fatalities per year worldwide, with 1.1 million owing to cirrhosis problems and 0.95 million due to viral hepatitis and hepatocellular cancer. Cirrhosis is thus the 12th largest cause of mortality globally, whereas liver cancer is the 17th leading cause of death. They are responsible for 3.2% of all fatalities worldwide. In addition, chronic liver disease fatality in the United States is predicted to climb, owing mostly to an increase in nonalcoholic fatty liver disease. The increased prevalence of liver illnesses aided in the market's growth. As a result, rising liver disease rates have aided in overall market growth.

Non-alcoholic Steatohepatitis Therapeutics Market, by Distribution Channel in 2022(%)

Obesity and viral hepatitis are the leading causes of liver disease in the United Kingdom. Furthermore, around 1110 liver transplants are conducted each year, and patients are reliant on market therapies because of a lack of liver donors. All of the aforementioned reasons are projected to drive the market's growth.

The objective of the report is to present a comprehensive analysis of the Non-alcoholic Steatohepatitis Therapeutics market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Non-alcoholic Steatohepatitis Therapeutics market dynamics, structure by analyzing the market segments and projecting the Non-alcoholic Steatohepatitis Therapeutics market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Non-alcoholic Steatohepatitis Therapeutics market make the report investor’s guide.

Non-alcoholic Steatohepatitis Therapeutics Market Scope: Inquiry Before Buying

Non-alcoholic Steatohepatitis Therapeutics Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)

Non-alcoholic Steatohepatitis Therapeutics Market, Key Players are

1. Galmed Pharmaceuticals Ltd.
2. Gilead Science
3. Tobira Therapeutics, Inc.
4. AstraZeneca Plc.
5. Conatus Pharmaceuticals
6. Enzo Biochem, Inc.
7. Immuron Ltd.
8. Intercepts Pharmaceuticals
9. Novo Nordisk
10. Raptor Pharmaceutical Corporation
11. Genfit SA
12. MediciNova
13. Shire
14. Viking Therapeutics
15. Zydus Cadila
16. Allergan plc.
17. Cadila Healthcare Limited
18. Gemphire Therapeutics Inc.
19. Gilead Sciences, Inc.

FAQs:

1. Which is the potential market for the Non-alcoholic Steatohepatitis Therapeutics in terms of the region?
Ans. chronic liver disease fatality in the United States is predicted to climb, owing mostly to an increase in nonalcoholic fatty liver disease.

2. What are the opportunities for new market entrants?
Ans. The key opportunity in the market is rising research and development investments in pharmaceutical companies.

3. What is expected to drive the growth of the Non-alcoholic Steatohepatitis Therapeutics market in the forecast period?
Ans. A primary driver of the market in the forecast period is expected to be the fact that many coronavirus patients have been diagnosed with liver diseases.

4. What is the projected market size & growth rate of the Non-alcoholic Steatohepatitis Therapeutics Market?
Ans. Non-alcoholic Steatohepatitis Therapeutics Market size was valued at US$ 10.58 Bn. in 2022 and the total Non-alcoholic Steatohepatitis Therapeutics revenue is expected to grow at 21.3% through 2023 to 2029, reaching nearly US$ 40.91 Bn.

5. What segments are covered in the Non-alcoholic Steatohepatitis Therapeutics Market report?
Ans. The segments covered are Diagnostic, Drug, Distribution Channel, and Region